Kintara’s VAL-083 Receives the US FDA’s Fast Track Designation for the Treatment of Newly Diagnosed Glioblastoma
Shots:
- The US FDA has granted FTD for VAL-083 to support the development and commercialization of VAL-083 for the treatment of patients with newly-diagnosed unmethylated glioblastoma
- Based on internal research programs and prior NCI-sponsored clinical studies, VAL-083 is currently evaluating an ongoing P-II/III study (GBM AGILE) and plans to present the data in the YE’23
- VAL-083 is a first-in-class small molecule that showed clinical activity in various cancers incl. CNS, head and neck cancer, NSCLC, ovarian & bladder cancer in the US that were sponsored by the National Cancer Institute
Ref: PR Newswire | Image: Kintara
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
